Search

Displaying results 2451 - 2460 of 10000 in total
  1. Drug

    Phosphatidyl serine

    go.drugbank.com/drugs/DB00144
    ApprovedNutraceutical

    PS has been investigated in a small number of double-blind placebo trials and has been shown to increase memory performance in the elderly. … PS has been shown to slow cognitive decline in animal models.

  2. Drug

    Onion

    go.drugbank.com/drugs/DB10548
    Approved

    Onion allergenic extract is used in allergenic testing.

    Mixtures: BARICUS 50 IU/%1/%10 JEL , 50 G, NOSKAR 100 MG/50 IU/10 MG / G, JEL 120 G
  3. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [A274848, A274853, A274858] Elevated APRIL levels are often observed in inflammatory disorders, including immunoglobulin A nephropathy (IgAN).

  4. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L51998,A264878] This novel mechanism of action is effective even in the presence of inhibitors towards factors VIII or IX, as it essentially skips the intrinsic pathway in which factors VIII and IX participate … [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors.

  5. Drug

    Poractant alfa

    go.drugbank.com/drugs/DB09113
    ApprovedInvestigational

    Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. … It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency.

  6. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]

  7. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital … [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric

  8. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

    Categories: Corticosteroids, Moderately Potent (Group II)
  9. Drug

    Methyclothiazide

    go.drugbank.com/drugs/DB00232
    ApprovedWithdrawn

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

  10. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    [A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses. … Ulobetasol is a highly potent corticosteroid.[A215597] It is structurally related to [clobetasol].